Merck & Co., Inc.

Equities

MRK

US58933Y1055

Market Closed - Nyse Other stock markets 04:00:02 2026-02-13 pm EST			5-day change	1st Jan Change
121.41 ^USD	+1.82%		-0.43%	+15.34%

Feb. 13	Merck Shares Rise After Deutsche Bank Upgrade	MT
Feb. 13	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid January Consumer Price Inflation Report	MT

Transcript : Merck & Co., Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 04

Published on 01/12/2026 at 08:50 pm EST - Modified on 01/12/2026 at 10:20 pm EST

S&P Capital IQ

Presenter Speech
Christopher Schott (Analysts)

Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Merck today. From the company, we have CEO, Rob Davis; as

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Merck & Co., Inc.

Feb. 13	Merck Shares Rise After Deutsche Bank Upgrade	MT
Feb. 13	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid January Consumer Price Inflation Report	MT
Feb. 13	Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115	MT
Feb. 13	Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115	MT
Feb. 12	Merck & Co. Insider Sold Shares Worth $1,214,562, According to a Recent SEC Filing	MT
Feb. 12	Argus Adjusts Price Target on Merck to $130 From $110, Maintains Buy Rating	MT
Feb. 12	Merck Advances Treatment of Bladder and Kidney Cancers with New Data At 2026 ASCO GU Cancers Symposium	CI
Feb. 11	Sector Update: Health Care Stocks Rise Late Afternoon	MT
Feb. 11	Sector Update: Health Care Stocks Advance Wednesday Afternoon	MT
Feb. 11	Sector Update: Health Care	MT
Feb. 11	Daiwa Securities Adjusts PT on Merck & Co. to $120 From $86, Maintains Neutral Rating	MT
Feb. 11	Merck Announces the U.S. Food and Drug Administration Approves KEYTRUDA (Pembrolizumab and Berahyaluronidase Alfa-Pmph) and KEYTRUDA QLEX	CI
Feb. 11	Agilent's Ovarian Cancer Diagnostic Test Receives FDA Clearance	MT
Feb. 11	Merck Says US FDA Approves Keytruda Combination in Platinum-Resistant Ovarian Cancer	MT
Feb. 10	Merck & Co. Insider Sold Shares Worth $1,202,844, According to a Recent SEC Filing	MT